Shunjing Pharma Unveils Novel Bispecific Antibody SGT003 at J.P. Morgan Healthcare Conference

At the 43rd J.P. Morgan Healthcare Conference (JPM), a focal point of global attention in the healthcare industry, SGT003, an innovative bispecific antibody developed by Shunjing Biopharma—an innovative drug company incubated by Hotgen Biotech (SH688068), a company listed on the STAR Market—made a stunning debut. It showcased the “Chinese solution” for innovative biologics to the world, drawing widespread attention from attendees.

Shunjing Biopharma’s bispecific antibody platform demonstrates superior antibody performance, overcoming the limitations of existing therapeutic regimens. Leveraging this platform, Shunjing Biopharma has established a portfolio of oncology pipelines. At the recent JPM Conference, following the announcement of research progress on SGC001, the world’s first emergency antibody drug for myocardial infarction, Shunjing Biopharma once again released data on the progress of SGT003, its core anti-tumor pipeline candidate.

The bispecific antibody SGT003 targets immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment. Preclinical data demonstrate that SGT003 significantly reduces the abundance of Tregs and tumor-associated macrophages (TAMs). At lower doses, SGT003 exhibits more potent antitumor efficacy than marketed anti-PD-1 and anti-CTLA-4 monoclonal antibodies, without inducing the release of cytokines such as TNF-α, thereby substantially improving safety and highlighting its superior therapeutic profile. Furthermore, SGT003 treatment enables the establishment of antitumor immune memory in animal models, effectively preventing tumor recurrence. SGT003 has the potential to become a more effective and safer next-generation cornerstone first-line agent for cancer immunotherapy.

Shunjing Medicine, an innovative drug company incubated by the STAR Market-listed Hotgen Biotech (SH688068), is an innovation-driven biopharmaceutical technology company dedicated to the discovery, development, and commercialization of original first-in-class (FIC) antibody drugs. Leveraging its outstanding scientific research and innovative drug development capabilities, the company has established a series of world-class technical platforms. Guided by unmet clinical needs, it has built a robust pipeline of original biologic macromolecule drug candidates with significant market potential, covering the treatment of various diseases such as cardiovascular and cerebrovascular disorders, cancer, and neurodegenerative conditions. This endeavor aims to enhance China’s new quality productive forces and benefit human health.

The JPM Conference is one of the largest and most information-rich premier events in the global healthcare sector, serving as a bellwether for development and investment in the global pharmaceutical and health industries. Shunjing Biopharma’s core bispecific antibody product, SGT003, made a prominent appearance at the JPM Conference, showcasing the company’s technological innovation capabilities on its bispecific antibody platform and marking a breakthrough progress by Shunjing Biopharma in the field of tumor immunotherapy. Shunjing Biopharma will accelerate the global commercialization process of SGT003, striving to provide safer and more effective innovative treatment options for cancer patients worldwide.